Session » Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1296

A Novel Potent and Selective Urate Transporter 1 Inhibitor, NC-2700, with pH-Raising Effect on Low Urinary pH

9:00AM-11:00AM: Abstract Number: 1299

A Novel Recombinant Oral Urate Oxidase (UrOx) Alln-346 Reduces Severe Hyperuricemia and Normalizes Hyperuricosuria in Nephropathic Urox Knockout (UrOxKO) Mice

9:00AM-11:00AM: Abstract Number: 1277

A Prospective Study Examining the Prevalence of CT Erosions in the Feet and Ankles of Patients with Gout Treated with Allopurinol

9:00AM-11:00AM: Abstract Number: 1266

ABCG2 rs2231142 Q141K and Oxypurinol Concentration in People with Gout Receiving Allopurinol

9:00AM-11:00AM: Abstract Number: 1295

Anakinra Is More Effective at Reducing Pain from Acute Crystal Induced Arthritis When Compared to Conventional Therapy: A Retrospective Review at a Tertiary Care Center

9:00AM-11:00AM: Abstract Number: 1268

Assessment of the Persistence of Crystals Under Polarised Light Microscopy in Stored Synovial Fluid Samples

9:00AM-11:00AM: Abstract Number: 1288

Association between Musculoskeletal Ultrasonography and Bone Remodeling Markers and the Role of Ultrasonography on Monitoring Treatment Responsiveness in Patients with Gout and Hyperuricemia

9:00AM-11:00AM: Abstract Number: 1281

Association of HFE Genotypes with Clinical Severity in Patients with Definite Calcium Pyrophosphate Arthritis

9:00AM-11:00AM: Abstract Number: 1274

Atmospheric Temperature and the Incidence of Gout Flare: Data from the Korea Meteorological Association and National Health Insurance Service

9:00AM-11:00AM: Abstract Number: 1283

Calcium Pyrophosphate Crystal Deposition in a Cohort of 48 Patients with Gitelman Syndrome

9:00AM-11:00AM: Abstract Number: 1285

Comparision of Urate Burden in Well and Poorly Controlled Gout Patients: A Dual-Energy CT Study

9:00AM-11:00AM: Abstract Number: 1275

Dual-Energy CT for the Diagnosis of Gout: A Prospective Study in Patients with No Prior History of Gout

9:00AM-11:00AM: Abstract Number: 1276

Effect of Colchicine on Diabetes Incidence Among Gout Patients in a Veterans’ Affairs Population

9:00AM-11:00AM: Abstract Number: 1291

Efficacy and Safety of Anakinra in Congestive Heart Failure Patients, Including Lvad, with Acute Gouty Arthritis: A Retrospective Study of 36 Patients at an Academic Medical Center

9:00AM-11:00AM: Abstract Number: 1278

Evaluating a Causal Role of Mitochondrial Variation in the Development of Gout

9:00AM-11:00AM: Abstract Number: 1298

Gout and the Risk of Parkinson’s Disease in Older Adults: A Study of U.S. Medicare Data

9:00AM-11:00AM: Abstract Number: 1280

Higher Body Fat Percentage in Non-Obese Late-Onset Gout Patients

9:00AM-11:00AM: Abstract Number: 1292

HLA-B*58:01 Genotype and the Risk of Allopurinol-Associated Severe Cutaneous Adverse Reactions in a Predominately Black or African American Population with Advanced Chronic Kidney Disease

9:00AM-11:00AM: Abstract Number: 1293

Identification of New and Rare Variants in ABCG2, SLC22A1 and ALDH16A1 Genes in Crystal-Proven Early-Onset Gout

9:00AM-11:00AM: Abstract Number: 1289

Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplant Population

9:00AM-11:00AM: Abstract Number: 1269

Influence of Diuretic-Response Sodium Transporter Genes on Renal Uric Acid Handling in Response to Frusemide

9:00AM-11:00AM: Abstract Number: 1282

Influence of Renal Function on the Velocity of Tophus Resolution and Achievement of Disease Remission in Patients with Chronic Refractory Gout Treated with Pegloticase

9:00AM-11:00AM: Abstract Number: 1284

Initial Pegloticase Serum Levels Predict Persistent Responsiveness in Patients with Chronic Refractory Gout

9:00AM-11:00AM: Abstract Number: 1294

Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin Enables Sustained Reduction of Acute Gout Flares

9:00AM-11:00AM: Abstract Number: 1270

Lack of Association of Comorbidities with Ultrasonographic Urate Deposition in Asymptomatic Hyperuricemia

9:00AM-11:00AM: Abstract Number: 1302

Opioid Analgesic Use in Acute Gout Patients Discharged from the Hospital

9:00AM-11:00AM: Abstract Number: 1301

Organic Anion Transport Inhibitors Suppress Chondrocyte Pyrophosphate Production

9:00AM-11:00AM: Abstract Number: 1271

Predictive Factors of Increased Vascular Stiffness in Patient with Gout and Hyperuricemia

9:00AM-11:00AM: Abstract Number: 1286

Pretreatment and Coadministration with Methotrexate Improved Durability of Pegloticase (Krystexxa) Response: A Prospective, Proof-of-Concept, Case Series

9:00AM-11:00AM: Abstract Number: 1272

Quality of Gout Management in a Rheumatology Clinic Using a Provider-Pharmacist Team-Based Approach

9:00AM-11:00AM: Abstract Number: 1279

Relative Insufficiency of Renal Uric Acid Excretion in Gout Patients with Obesity Leads to High Serum and Glomerular Filtration Load of Uric Acid

9:00AM-11:00AM: Abstract Number: 1297

Risk of Dementia in Patients with Gout and the Impact of Urate-Lowering Therapies: A Large Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 1287

Strong Impact of Dysfunctional Variants of ABCG2 on Hyperuricemia and Gout in Children and Adolescents

9:00AM-11:00AM: Abstract Number: 1290

Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study

9:00AM-11:00AM: Abstract Number: 1267

The Association between Clinically Suspect Arthralgia and Adipokines in Obese Patients

9:00AM-11:00AM: Abstract Number: 1265

The Challenges of Managing Gout in Primary Care: Results of a Best Practice Audit

9:00AM-11:00AM: Abstract Number: 1300

The Relationship between Metabolic Syndrome Severity and the Risk of Mortality in Gout Patients: A Population Based Study

9:00AM-11:00AM: Abstract Number: 1273

What Did Patients from the US Think about Their Gout in 2017?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].